Compare SVRA & ANDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVRA | ANDG |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2009 | 2025 |
| Metric | SVRA | ANDG |
|---|---|---|
| Price | $4.90 | $66.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $11.06 | ★ $61.29 |
| AVG Volume (30 Days) | ★ 2.7M | 411.5K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $838,692,000.00 |
| Revenue This Year | N/A | $18.38 |
| Revenue Next Year | $9,266.31 | $18.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.64 |
| 52 Week Low | $4.13 | $18.12 |
| 52 Week High | $7.01 | $68.41 |
| Indicator | SVRA | ANDG |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 68.09 |
| Support Level | $4.73 | $52.10 |
| Resistance Level | $5.47 | $68.41 |
| Average True Range (ATR) | 0.32 | 2.53 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 61.07 | 76.52 |
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Andersen Group Inc is a provider of independent tax, valuation, and financial advisory services to individuals and family offices, businesses, and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services. The firm generates the key revenue from Private Client Services, which provide comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving, and trust and estate planning.